Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone speaks to Proactive London's Andrew Scott after announcing they're soon to kick off a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. He says it's due to start in the next few weeks with clinical data potentially available before the end of 2020. As part of the trial Foralumab will be used either alone or in combination with orally administered dexamethasone.